CINV=chemotherapy-induced nausea and vomiting.
MEC=moderately emetogenic chemotherapy.
HEC=highly emetogenic chemotherapy.
- SUSTOL is indicated for the prevention of CINV due to MEC and AC combination chemotherapy.1
- SUSTOL [prescribing information]. Heron Therapeutics, Inc., San Diego, CA; May 2017.
- Aloxi [prescribing information]. Helsinn Therapeutics (U.S.), Inc., Iselin, NJ; September 2018.
- Zofran [prescribing information]. GlaxoSmithKline, Research Triangle Park, NC; October 2017.
- Kytril [prescribing information]. Genentech, Inc., South San Francisco, CA; April 2011.
- Sancuso [prescribing information]. ProStrakan Inc., Bridgewater, NJ; January 2017.
- Anzemet [prescribing information]. Sanofi-Aventis U.S. LLC, Bridgewater, NJ; June 2016.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed April 23, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.